DISCLAIMER: This analysis in no way should be considered investment advice! In an effort to keep the modeling skills a bit more than dull combined with a deep-rooted curiosity about the development or lack-there-of by big pharma of new anti-infectives I remain fascinated with the progression of Replidyne’s (NASDAQ: RDYN) portfolio, particularly the antibiotic Faropenem [...]